UA76106C2 - Formulation containing factor viia and factor xiii, set for intravenous administration, method for increasing generation of fibrin clots, method for treatment or prophylaxis of bleeding episodes, use of factor viia or factor xiii for manufacturing drug for treatment or prophylaxis of bleeding episodes - Google Patents
Formulation containing factor viia and factor xiii, set for intravenous administration, method for increasing generation of fibrin clots, method for treatment or prophylaxis of bleeding episodes, use of factor viia or factor xiii for manufacturing drug for treatment or prophylaxis of bleeding episodes Download PDFInfo
- Publication number
- UA76106C2 UA76106C2 UA2002118784A UA2002118784A UA76106C2 UA 76106 C2 UA76106 C2 UA 76106C2 UA 2002118784 A UA2002118784 A UA 2002118784A UA 2002118784 A UA2002118784 A UA 2002118784A UA 76106 C2 UA76106 C2 UA 76106C2
- Authority
- UA
- Ukraine
- Prior art keywords
- factor
- miia
- xii
- effective amount
- bleeding
- Prior art date
Links
- 208000032843 Hemorrhage Diseases 0.000 title claims abstract description 78
- 208000034158 bleeding Diseases 0.000 title claims abstract description 78
- 230000000740 bleeding effect Effects 0.000 title claims abstract description 78
- 238000011282 treatment Methods 0.000 title claims abstract description 37
- 229940012444 factor xiii Drugs 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 title claims description 59
- 238000000034 method Methods 0.000 title claims description 41
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title claims description 34
- 102000009123 Fibrin Human genes 0.000 title claims description 33
- 108010073385 Fibrin Proteins 0.000 title claims description 33
- 229950003499 fibrin Drugs 0.000 title claims description 33
- 238000004519 manufacturing process Methods 0.000 title claims description 23
- 230000001965 increasing effect Effects 0.000 title claims description 13
- 239000003814 drug Substances 0.000 title claims description 10
- 238000001990 intravenous administration Methods 0.000 title claims description 8
- 229940079593 drug Drugs 0.000 title claims 2
- 238000011321 prophylaxis Methods 0.000 title abstract description 4
- 229940012414 factor viia Drugs 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title description 2
- 108010071289 Factor XIII Proteins 0.000 claims abstract description 19
- 108010080865 Factor XII Proteins 0.000 claims description 79
- 102000000429 Factor XII Human genes 0.000 claims description 79
- 239000003937 drug carrier Substances 0.000 claims description 52
- 239000003112 inhibitor Substances 0.000 claims description 42
- 239000002552 dosage form Substances 0.000 claims description 24
- 230000009089 cytolysis Effects 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 230000015572 biosynthetic process Effects 0.000 claims description 17
- 230000035602 clotting Effects 0.000 claims description 14
- 239000000539 dimer Substances 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000013256 coordination polymer Substances 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 229940126601 medicinal product Drugs 0.000 claims 6
- 230000001667 episodic effect Effects 0.000 claims 3
- 108010054265 Factor VIIa Proteins 0.000 abstract 1
- 108090000190 Thrombin Proteins 0.000 description 39
- 229960004072 thrombin Drugs 0.000 description 39
- 230000000694 effects Effects 0.000 description 33
- 230000023597 hemostasis Effects 0.000 description 22
- 230000015271 coagulation Effects 0.000 description 18
- 238000005345 coagulation Methods 0.000 description 18
- 150000001413 amino acids Chemical group 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 13
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 13
- 208000009292 Hemophilia A Diseases 0.000 description 13
- 239000003114 blood coagulation factor Substances 0.000 description 13
- 230000002439 hemostatic effect Effects 0.000 description 13
- 230000004913 activation Effects 0.000 description 11
- 108010049003 Fibrinogen Proteins 0.000 description 10
- 102000008946 Fibrinogen Human genes 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 229940012952 fibrinogen Drugs 0.000 description 10
- 230000020764 fibrinolysis Effects 0.000 description 10
- 235000002639 sodium chloride Nutrition 0.000 description 10
- 230000006378 damage Effects 0.000 description 9
- 230000001771 impaired effect Effects 0.000 description 9
- 208000014674 injury Diseases 0.000 description 9
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 9
- 239000003755 preservative agent Substances 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 206010053567 Coagulopathies Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 239000003599 detergent Substances 0.000 description 8
- 230000003480 fibrinolytic effect Effects 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102000010911 Enzyme Precursors Human genes 0.000 description 7
- 108010062466 Enzyme Precursors Proteins 0.000 description 7
- 208000031220 Hemophilia Diseases 0.000 description 7
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 7
- 108010000499 Thromboplastin Proteins 0.000 description 7
- 102000002262 Thromboplastin Human genes 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 239000003527 fibrinolytic agent Substances 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 230000002335 preservative effect Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000003381 stabilizer Substances 0.000 description 7
- 206010043554 thrombocytopenia Diseases 0.000 description 7
- 230000008733 trauma Effects 0.000 description 7
- 102100026735 Coagulation factor VIII Human genes 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 201000003542 Factor VIII deficiency Diseases 0.000 description 6
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 102100022641 Coagulation factor IX Human genes 0.000 description 5
- 108010094028 Prothrombin Proteins 0.000 description 5
- 208000015294 blood coagulation disease Diseases 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 208000009429 hemophilia B Diseases 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000011477 surgical intervention Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- -1 /-aminocaproic acid Chemical compound 0.000 description 4
- 108010039627 Aprotinin Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 108010014173 Factor X Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102100027378 Prothrombin Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 229960004405 aprotinin Drugs 0.000 description 4
- 239000000701 coagulant Substances 0.000 description 4
- 230000009852 coagulant defect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 229940039716 prothrombin Drugs 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000000451 tissue damage Effects 0.000 description 4
- 231100000827 tissue damage Toxicity 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010074864 Factor XI Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 208000027276 Von Willebrand disease Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229940019700 blood coagulation factors Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 3
- 229960000401 tranexamic acid Drugs 0.000 description 3
- 230000003462 zymogenic effect Effects 0.000 description 3
- MYLBTCQBKAKUTJ-UHFFFAOYSA-N 7-methyl-6,8-bis(methylsulfanyl)pyrrolo[1,2-a]pyrazine Chemical compound C1=CN=CC2=C(SC)C(C)=C(SC)N21 MYLBTCQBKAKUTJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010067787 Coagulation factor deficiency Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 108010071241 Factor XIIa Proteins 0.000 description 2
- 206010017866 Gastritis haemorrhagic Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000004221 Multiple Trauma Diseases 0.000 description 2
- 208000023637 Multiple injury Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 206010073391 Platelet dysfunction Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 2
- 108060008539 Transglutaminase Proteins 0.000 description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 208000014763 coagulation protein disease Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000003027 ear inner Anatomy 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 239000003805 procoagulant Substances 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 102000003601 transglutaminase Human genes 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102100029117 Coagulation factor X Human genes 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 101100291267 Drosophila melanogaster Miga gene Proteins 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 208000032371 Glanzmann thrombasthenia 1 Diseases 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010090444 Innovin Proteins 0.000 description 1
- 108010077861 Kininogens Proteins 0.000 description 1
- 102000010631 Kininogens Human genes 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 244000234179 Myrtus ugni Species 0.000 description 1
- 235000012093 Myrtus ugni Nutrition 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000113 Plasma Kallikrein Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000000392 Thrombasthenia Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 101710139626 Tissue factor pathway inhibitor Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- NHJPVZLSLOHJDM-UHFFFAOYSA-N azane;butanedioic acid Chemical compound [NH4+].[NH4+].[O-]C(=O)CCC([O-])=O NHJPVZLSLOHJDM-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940105756 coagulation factor x Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000004453 electron probe microanalysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- JPKNLFVGUZRHOB-YUMQZZPRSA-N epsilon-(gamma-glutamyl)lysine Chemical compound OC(=O)[C@@H](N)CCCCNC(=O)CC[C@H](N)C(O)=O JPKNLFVGUZRHOB-YUMQZZPRSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004835 fabric adhesive Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940005809 human factor xiii Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 229940124592 pro-hemostatic agent Drugs 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011473 radical retropubic prostatectomy Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940019333 vitamin k antagonists Drugs 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200000778 | 2000-05-10 | ||
| PCT/DK2001/000322 WO2001085198A1 (en) | 2000-05-10 | 2001-05-10 | tHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIA AND A FACTOR XIII |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA76106C2 true UA76106C2 (en) | 2006-07-17 |
Family
ID=29594967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2002118784A UA76106C2 (en) | 2000-05-10 | 2001-10-05 | Formulation containing factor viia and factor xiii, set for intravenous administration, method for increasing generation of fibrin clots, method for treatment or prophylaxis of bleeding episodes, use of factor viia or factor xiii for manufacturing drug for treatment or prophylaxis of bleeding episodes |
Country Status (3)
| Country | Link |
|---|---|
| RU (1) | RU2272648C2 (ru) |
| UA (1) | UA76106C2 (ru) |
| ZA (1) | ZA200208695B (ru) |
-
2001
- 2001-05-10 RU RU2002133046/15A patent/RU2272648C2/ru not_active IP Right Cessation
- 2001-10-05 UA UA2002118784A patent/UA76106C2/uk unknown
-
2002
- 2002-10-28 ZA ZA200208695A patent/ZA200208695B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2272648C2 (ru) | 2006-03-27 |
| ZA200208695B (en) | 2003-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1282439B1 (en) | PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A TFPI INHIBITOR | |
| US8394768B2 (en) | Synergistic therapeutic use of Prothrombin Complex Concentrates with FVIII concentrates | |
| US20030073638A1 (en) | Pharmaceutical composition comprising factor VIIa and anti-TFPI | |
| KR20030078901A (ko) | 인자 ⅶ 폴리펩티드 및 인자 ⅷ 폴리펩티드의 조합 사용 | |
| AU2001258228A1 (en) | Pharmaceutical composition comprising a factor VIIA and a factor XIII | |
| Liebman et al. | Increased fibrinolysis and amyloidosis | |
| JP2005526004A (ja) | 第ｖｉｉ因子ポリペプチドおよびトラネキサム酸を含む薬学的組成物 | |
| JP5236952B2 (ja) | 改善された特性を有するｆｘｉｉｉバリアント | |
| UA76106C2 (en) | Formulation containing factor viia and factor xiii, set for intravenous administration, method for increasing generation of fibrin clots, method for treatment or prophylaxis of bleeding episodes, use of factor viia or factor xiii for manufacturing drug for treatment or prophylaxis of bleeding episodes | |
| EP1128842B1 (en) | Use of human protein c for the manufacture of a medicament for treating heparin-induced thrombocytopenia | |
| EP1137432B1 (en) | Use of protein c for the treatment of thrombocytopenic purpura and hemolytic uremic syndrome | |
| Perry | Factor X and Factor X deficiency | |
| TWI287452B (en) | Pharmaceutical composition comprising a factor VIIa and a factor XIII | |
| MXPA03005641A (es) | Uso de factor vii activado de coagulacion para tratar sangrados graves inducidos por terapia trombolitica. | |
| KR20020092469A (ko) | 인자 ＶＩＩａ 및 인자 ＸＩＩＩ를 포함하는 제약학적조성물 | |
| MXPA02011042A (en) | tHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIA AND A FACTOR XIII | |
| JP2004513150A (ja) | Ｂ型血友病の治療方法 | |
| JP2005515175A (ja) | 第ｖｉｉ因子ポリペプチドおよびアルファ２−抗プラスミンポリペプチドを含む薬学的組成物 | |
| JPH09176041A (ja) | α２プラスミンインヒビターを含有するＤＩＣ治療用薬剤 | |
| MXPA01005689A (en) | Method of treating thrombocytopenic purpura and hemolytic uremic syndrome |